LXA4 |
Bacteria |
In general, beneficial effects
against different types of bacteria. Administration of LXA4 is
associated with diminished production of pro-inflammatory mediators and
enhanced efficacy of bacterial clearance when administered with
antibiotics. |
Resolvins |
Virus |
Overall, Resolvins display
anti-inflammatory and protection from tissue damage without affecting
viral load. |
|
Bacteria |
Robust evidence demonstrates that different types
of resolvins decrease inflammation, enhance bacterial clearance and
increase efferocytosis. |
Maresins |
Bacteria |
Despite little data, evidence
suggests pro-resolutive effects, such as decreased inflammation and
bacterial burden. |
Protectins |
Bacteria |
Overall, administration of
PD1 is associated with decreased bacterial burden and increased
production of anti-inflammatory mediators. |
|
Virus |
PD1 administration decreased both inflammation and
viral loads against different viruses, such as RSV, HSV, H1N1 and
H5N1. |
GILZ |
Bacteria |
Evidence points towards to
pro-resolutive effects depending on the host cell and bacteria
type. |
AnxA1 |
Bacteria |
In most of the studies, AnxA1 and
Ac2-26 were associated with diminished inflammation and enhanced
bacterial clearance. |
|
Virus |
Accelerated resolution and decreased inflammation of
endogenous AnxA1 and Ac2-26 treatment against arbovirus
infections. |
Angio (1-7) |
Virus |
Ang-(1-7) reduces exacerbated
inflammatory response, increases apoptosis and efferocytosis of
neutrophils in the lung, reduces lung damage and reduces Influenza A
virus in the lung. |
|
Bacteria |
Ang-(1-7) prevents sepsis, bacterial burden in the
lung, recovers ability of neutrophils to phagocytize, decreases
macrophage polarization towards the M1 and promoted it to the M2 and
controls exacerbated inflammatory response. |